Literature DB >> 2944502

Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions.

C F Platell, E G Tan.   

Abstract

Significant hypersensitivity reactions to heparin may manifest as either delayed onset thrombocytopenia or as necrotizing skin lesions. Such hypersensitivity reactions are uncommonly recognized, partly because of their rarity and partly because their existence is not widely appreciated. Both adverse reactions may be readily diagnosed. In the presence of these reactions, continuing heparin therapy may lead to serious thrombo-embolic complications and death of the patient. In this study, two patients who highlight the clinical settings of these reactions are discussed with reference to their pathogenesis and clinical significance.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944502     DOI: 10.1111/j.1445-2197.1986.tb04516.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


  5 in total

1.  Hypersensitivity to nadroparin calcium : case report and review of the literature.

Authors:  Didier G Ebo; Steven E Haine; Margo M Hagendorens; Chris H Bridts; Viviane M Conraads; Ann Vorlat; Chris J Vrints; Luc S De Clerck; Wim J Stevens
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 2.  Heparin-induced skin necrosis and low molecular weight heparins.

Authors:  P J Drew; M J Smith; M A Milling
Journal:  Ann R Coll Surg Engl       Date:  1999-07       Impact factor: 1.891

3.  Delayed-onset heparin-induced skin necrosis: a rare complication of perioperative heparin therapy.

Authors:  Weh Kiat Gan
Journal:  BMJ Case Rep       Date:  2017-11-03

4.  The direct medical costs associated with suspected heparin-induced thrombocytopenia.

Authors:  Natasha Nanwa; Nicole Mittmann; Sandra Knowles; Claudia Bucci; Rita Selby; Neil Shear; Scott E Walker; William Geerts
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

Review 5.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.